Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8474072 | 0.84 | KDM4E (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL5107992 | 0.78 | KDM4E (0.44) | KDM4EALDH1A1LMNADCTPP1 | |
| SCHEMBL8479028 | 0.77 | KDM4E (0.34) | KDM4EALDH1A1TSHR | |
| SCHEMBL6871464 | 0.70 | ADRA2A (0.49) | KDM4EALDH1A1DCTPP1 | |
| SCHEMBL9381464 | 0.69 | NPC1 (0.47) | KDM4EALDH1A1TSHR | |
| SCHEMBL3618682 | 0.69 | CYP2C9 (0.39) | KDM4EALDH1A1LMNA | |
| SCHEMBL7143254 | 0.67 | HTR2A (0.36) | — | |
| SCHEMBL1779591 | 0.67 | SMN1; SMN2 (0.44) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL14678035 | 0.65 | CYP1A2 (0.41) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL1780224 | 0.62 | KDM4E (0.35) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371769-B2 | Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-05-13 | — | — | US | disclosed |
| US-20070066634-A2 | TETRAHYDROPYRIDIN-4-YL INDOLES WITH A COMBINATION OF AFFINITY FOR DOPAMINE-D2 RECEPTORS AND SEROTONIN REUPTAKE SITES | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-03-22 | — | — | US | disclosed |
| US-20060122206-A1 | Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122206-A1 | Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites | SLC6A3, HTR3C, DRD3 | KDM4E 4257/4885USP2 2686/4885ALDH1A1 1366/4885 |
| US-20070066634-A2 | TETRAHYDROPYRIDIN-4-YL INDOLES WITH A COMBINATION OF AFFINITY FOR DOPAMINE-D2 RECEPTORS AND SEROTONIN REUPTAKE SITES | SLC6A3, HTR3C, DRD3 | KDM4E 4257/4885USP2 2686/4885ALDH1A1 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.